Stockscreener 앱 받기
1.97
7.51%
-0.16
시장 영업 전:
1.98
0.01
+0.51%
전일 마감가:
$2.13
열려 있는:
$2.17
하루 거래량:
1.19M
Relative Volume:
1.65
시가총액:
$142.42M
수익:
$208.60K
순이익/손실:
$-58.59M
주가수익비율:
-2.1497
EPS:
-0.9164
순현금흐름:
$-47.11M
1주 성능:
+17.96%
1개월 성능:
+115.91%
6개월 성능:
+58.87%
1년 성능:
+19.39%
1일 변동 폭
$1.925
$2.21
1주일 범위
$1.635
$2.21
52주 변동 폭
$0.7113
$2.21
Inflarx Nv Stock (IFRX) Company Profile
Compare IFRX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IFRX
Inflarx Nv
|
1.97 | 142.42M | 208.60K | -58.59M | -47.11M | -0.9164 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Inflarx Nv Stock (IFRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-03 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-09-02 | 재개 | H.C. Wainwright | Buy |
| 2025-05-29 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-04-05 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-02-28 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-10-28 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2021-03-11 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-06 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-10-08 | 개시 | H.C. Wainwright | Buy |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-04-30 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2019-06-05 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2019-06-05 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-05 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2019-06-05 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-06-05 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-01-29 | 개시 | Robert W. Baird | Outperform |
| 2018-12-10 | 개시 | Credit Suisse | Outperform |
| 2018-07-13 | 개시 | BMO Capital Markets | Outperform |
| 2018-06-28 | 개시 | Raymond James | Outperform |
| 2018-06-28 | 개시 | SunTrust | Buy |
| 2018-02-08 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
Inflarx Nv 주식(IFRX)의 최신 뉴스
InflaRx NV expected to post a loss of 14 cents a shareEarnings Preview - TradingView
InflaRx Highlights Favorable Safety-Signal Data for Izicopan in New Preclinical Study - TipRanks
Low reactive metabolite data support InflaRx (IFRX) oral C5aR1 drug - Stock Titan
InflaRx reports preclinical data on izicopan metabolite formation By Investing.com - Investing.com Canada
In liver lab tests, izicopan showed over 100-fold lower reactive conjugates - Stock Titan
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes - ChartMill
MSN Money - MSN
InflaRx regains Nasdaq compliance after shares trade above $1 - MSN
InfraRX Down Ahead of Next Quarterly Report - Baystreet.ca
IFRX - Finviz
InflaRx N.V. to Publish Q1 2026 Financial Results on May 7, 2026 - Quiver Quantitative
InflaRx to Report First Quarter 2026 Results on May 7, 2026 - ChartMill
InflaRx N.V. (NASDAQ:IFRX) Short Interest Update - MarketBeat
InflaRx (IFRX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
InflaRx Regains Nasdaq Minimum Bid Price Compliance, Securing Listing Status - TipRanks
InflaRx (Nasdaq: IFRX) back in line with Nasdaq minimum bid price rule - Stock Titan
InflaRx regains Nasdaq minimum bid price compliance By Investing.com - Investing.com Australia
Nasdaq closes InflaRx listing issue after stock holds above $1 - Stock Titan
InflaRx regains Nasdaq minimum bid price compliance - Investing.com
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement - marketscreener.com
InflaRx NV (IFRX) price target decreased by 17.33% to 9.03 - MSN
InflaRx Shareholders Approve Capital, Governance Changes and 2026 Incentive Plan at April AGM - The Globe and Mail
InflaRx (NASDAQ:IFRX) Coverage Initiated at Oppenheimer - MarketBeat
Oppenheimer Adjusts Price Target on InflaRx to $5 From $7, Maintains Outperform Rating - marketscreener.com
InflaRx receives Nasdaq notification - MSN
InflaRx (IFRX) investors back board authorities, article changes and LTIP 2026 - Stock Titan
Guggenheim reiterates Inflarx stock rating on AAV opportunity By Investing.com - Investing.com India
IFRX Reiterated by Guggenheim -- Price Target Maintained at $14 - GuruFocus
InflaRx's (IFRX) "Buy" Rating Reaffirmed at Guggenheim - MarketBeat
InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Guggenheim reiterates Inflarx stock rating on AAV opportunity - Investing.com
InflaRx N.V. (IFRX) Stock Mean Reversion (-1.57%) 2026-04-20Community Watchlist - Xã Vĩnh Công
Guggenheim Maintains InflaRx N.V. (IFRX) Buy Recommendation - MSN
IFRX Stock Soars Pre-Market After Experimental Drug Shows Promise In Treating Chronic Skin Diseases - MSN
Is InflaRx N.V. (IFRX) stock gaining bullish momentum (Parabolic) 2026-04-18Open Stock Picks - Xã Châu Thành
InflaRx (NASDAQ:IFRX) Stock Price Up 32.5%Should You Buy? - MarketBeat
Mark Kubler Net Worth (2026) - GuruFocus
Nicolas Fulpius Net Worth (2026) - GuruFocus
Hege Hellstrom Net Worth (2026) - GuruFocus
Derval Ocarroll Net Worth (2026) - GuruFocus
Renfeng Guo Net Worth (2026) - GuruFocus
Inflarx Nv (IFRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):